Studies
The iCARUS Research Portfolio
CURRENT STUDIES
START is a randomized controlled trial testing an mHealth app to optimize HIV treatment as prevention in sexual minority men living with HIV who use stimulants.
PARTI is a randomized controlled trial testing a positive affect intervention to increase pre-exposure prophylaxis (PrEP) adherence among sexual minority men who use stimulants.
TRIDENT is a randomized controlled trial examining whether and how depression treatment modifies the gut-brain axis in people with HIV.
AMETHST is a national cohort of HIV-negative sexual minority men examining whether methamphetamine use alters rectal immune function. It is a randomized controlled trial aimed at increasing the use of pre-exposure prophylaxis.
ARCHES is a national cohort study to identify the multi-level determinants that modify the associations of stimulant use with viral suppression and inflammation among sexual minority men with HIV.
PrEP-to-Bay is a pilot randomized controlled trial testing a motivational interviewing intervention to increase PrEP adherence in young sexual minority men with syndemic comorbidities.
MyTPill uses a counterbalanced design to determine the differential validity of two electronic adherence monitoring strategies (i.e. WisePill vs digital pills) in people with HIV who use opioids or stimulants.
TITAN is a randomized controlled trial testing novel, trauma-informed care approaches for Cambodian people with Post-Traumatic Stress Disorder (PTSD).
ARES is a 6-month, prospective cohort study assessing whether the use of methamphetamine triggers activation of the viral reservoir and may correlate with an increase in HIV clinical disease markers.
PAST STUDIES
The CRUSH study aimed to understand how COVID, HIV, and methamphetamine use impact sexual minority men.
PRISM 2.0 was a pilot sequential multiple assignment randomized controlled trial testing motivational enhancement interventions to increase PrEP use in sexual minority men who use stimulants.
PRISM 1.0 was a biobehavioral study conducted in the STI clinic setting to examine correlates of rectal immune function and the rectal microbiome.
ARTEMIS was a randomized controlled trial that demonstrated a positive affect intervention delivered during CM for stimulant abstinence achieved durable viral suppression in sexual minority men with HIV who use methamphetamine.